alzres.com/article
Bottom,Top,Right1
  • Log on
  •   BioMed Central
  • Journals
  • Gateways
Alzheimer's Research & Therapy
tracked for impact factor
Search for
Advanced search
  • Home
  • Articles
  • Authors
  • Reviewers
  • About this journal
  • My Alzheimer's Research & Therapy
  • Subscriptions

Submit a manuscript Register Sign up for article alerts Contact us Follow us on Twitter

Explore journal

  •  Editorial Board
  •  Instructions for authors
  •  FAQ
Advertisement

Articles

  • All articles RSS
  • Most viewed RSS
  • Issues
  • Supplements
  • Article collections
Supplements
Please provide a volume number.

Page 1 of 7

1 2 3 4 5 6 7  Next

 Display/download options Articles per page: 25 | 50 | 100

Display options
Download optionsHelp icon

Viewpoint   Subscription

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report

René Spiegel, Rachelle S Doody, Suzanne Hendrix, Kristin Kahle-Wrobleski Alzheimer's Research & Therapy 2013, 5:29 (17 June 2013)

Abstract | Full text | PDF |  Editor’s summary

Spiegel and colleagues present three approaches to improving and facilitating Alzheimer's disease clinical trials with anti-dementia drugs and discuss how current clinical trials should focus on incorporating these suggestions.

Research   Open Access

Exploring the Potential of the Platelet Membrane Proteome as a Source of Peripheral Biomarkers for Alzheimer's Disease

Laura E Donovan, Eric B Dammer, Duc M Duong, John J Hanfelt, Allan I Levey, Nicholas T Seyfried, James J Lah Alzheimer's Research & Therapy 2013, 5:32 (13 June 2013)

Abstract | Provisional PDF | PubMed |  Editor’s summary

The platelet membrane proteome may be a source of blood-based biomarkers in Alzheimer's disease (AD), particularly secretory granule protein levels, shows a comparative analysis in mild-to-moderate AD patients.

Review   Subscription

What boxing tells us about repetitive head trauma and the brain

Charles Bernick, Sarah Banks Alzheimer's Research & Therapy 2013, 5:23 (4 June 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Bernick and Banks review cross-sectional results from the first year of the Professional Fighters Brain Health Study to identify what boxing can tell us about repetitive head trauma and the brain.

Editorial   Free Highly Accessed

Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?

Douglas Galasko, Todd E Golde, Philip Scheltens Alzheimer's Research & Therapy 2013, 5:26 (29 May 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

In their editorial, Editors-in-Chief Douglas Galasko, Todd Golde and Philip Scheltens review the positive advances and challenges in Alzheimer's disease (AD) research circa 2013, and present news highlights from the journal.

Research   Open Access Highly Accessed

Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease

Scott J Webster, Adam D Bachstetter, Linda J Van Eldik Alzheimer's Research & Therapy 2013, 5:28 (24 May 2013)

Abstract | Provisional PDF | PubMed |  Editor’s summary

The APP/PS1 knock-in mouse model of Alzheimer's disease (AD) is well suited for preclinical testing of AD therapeutics as it shows age/disease-related cognitive decline without motor/coordination deficits or abnormal anxiety levels.

Review   Subscription Highly Accessed

Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease

Todd E Golde, Wolfgang J Streit, Paramita Chakrabarty Alzheimer's Research & Therapy 2013, 5:24 (21 May 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Golde and colleagues review the function of innate immune signalling in Alzheimer's disease (AD) following recent studies showing variants of TREM2, a triggering receptor on myeloid cells, is significantly associated with AD risk.

Commentary   Subscription

Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease

Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Research   Open Access Highly Accessed

The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice

Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, David Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).

Review   Subscription Highly Accessed

Advances in blood-based protein biomarkers for Alzheimer's disease

Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.

Review   Subscription

Modeling Alzheimer's disease with non-transgenic rat models

Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.

Review   Subscription

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease

Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.

Review   Subscription Highly Accessed

5-HT6 receptors and Alzheimer's disease

María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT6 receptor compounds, resulting in 5-HT6-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).

Research   Open Access Highly Accessed

Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model

Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.

Research   Open Access Highly Accessed

Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models

Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.

Review   Subscription Highly Accessed

DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease

Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.

Letter   Free

Plasma tau levels in Alzheimer's disease

Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013)

Abstract | Full text | PDF | PubMed

Research   Open Access

The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection

Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.

Debate   Subscription

Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.

Review   Subscription

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.

Review   Subscription

Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems

Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.

Research   Open Access Highly Accessed

Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment

Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.

Research   Open Access

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.

Editorial   Free

The C9ORF72 mutation brings more answers and more questions

Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013)

Abstract | Full text | PDF | PubMed |  Editor’s summary

Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.

Meeting report   Subscription

Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery

Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013)

Abstract | Full text | PDF | PubMed

Review   Subscription Highly Accessed

Alcohol-related dementia: an update of the evidence

Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central |  Editor’s summary

Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.

Page 1 of 7

1 2 3 4 5 6 7  Next


  • Terms and Conditions
  • Privacy statement
  • Press
  • Information for advertisers
  • Jobs at BMC
  • Support
  • Contact us

© 2013 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.